Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 8/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27664795 | 0.87 | TSHR (0.52) | ALDH1A1TDP1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL27788576 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TDP1TSHRGRIN2DGRIN3B | |
| SCHEMBL456292 | 0.75 | TSHR (0.50) | ALDH1A1TDP1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL1820951 | 0.72 | ALDH1A1 (0.58) | ALDH1A1TDP1TSHRHSD17B10ACHE | |
| SCHEMBL635089 | 0.72 | ALDH1A1 (1.00) | ALDH1A1TDP1TSHRHSD17B10ACHE | |
| SCHEMBL57836 | 0.72 | TSHR (0.40) | ALDH1A1TDP1TSHRHSD17B10CYP3A4 | |
| SCHEMBL28006835 | 0.72 | HSD17B10 (0.41) | ALDH1A1TDP1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL27631150 | 0.72 | CYP1A2 (0.48) | ALDH1A1TDP1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL458217 | 0.71 | POLB (0.41) | ALDH1A1TDP1TSHRGRIN2DGRIN3B | |
| SCHEMBL4427648 | 0.70 | ALDH1A1 (0.71) | ALDH1A1TDP1TSHRHSD17B10ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | claimed |
| JP-2012500216-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | claimed |
| EP-2318006-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 Pharmaceuticals, LLC (US) | 2011-05-11 | — | — | EP | claimed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | claimed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | claimed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | claimed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | claimed |
| CN-110662541-B | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2023-02-10 | — | — | CN | disclosed |
| CN-110662541-A | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2020-01-07 | — | — | CN | disclosed |
| EP-3339286-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-06-27 | — | — | EP | disclosed |
| EP-2427426-B1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-07 | — | — | EP | disclosed |
| EP-1163226-A1 | POLYSUBSTITUTED 6-PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-12-19 | — | — | EP | disclosed |
| CN-1280570-A | Substituted fused heterocyclic compounds | SANKYO CO (JP) | 2001-01-17 | — | — | CN | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000042018-A1 | POLYSUBSTITUTED 6-PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | ALDH1A1 449/4885TDP1 1293/4885TSHR 1312/4885 |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | ALDH1A1 2309/4885TDP1 1448/4885TSHR 3540/4885 |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | ALDH1A1 449/4885TDP1 1293/4885TSHR 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.